Announcing the TCT Connect Late-Breaking Trials and Science

NEW YORK – September 17, 2020 – The Cardiovascular Research Foundation (CRF) has announced over 30 late-breaking trial and science presentations that will be reported at TCT Connect. TCT, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place online October 14-18.

“Every year, TCT features major medical research breakthroughs that directly impact patient care, and this year is no different,” said Juan F. Granada, MD, President and Chief Executive Officer of CRF. “Data from these trials will impact how physicians treat heart disease by helping them improve and refine procedures and identifying the types of patients who would benefit most from treatment.”

The studies selected examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that demonstrate potential to treat or prevent cardiovascular disease.

Late-breaking trials and science will be presented on the Main Arena channel and highlighted during press conferences scheduled for Tuesday, October 13; Wednesday, October 14; Thursday, October 15; Friday, October 16; and Saturday, October 17. This year’s TCT Connect also includes a special endovascular late-breaking session.

The Program at a Glance can be found here: https://www.tctconnect.com/tct-program-glance/. Media are invited to attend TCT and can apply for media credentials online at: : https://www.tctconnect.com/tct-press-registration/.

Wednesday, October 14, 2020

Late-Breaking Trials

PROSPECT II: A Prospective Natural History Study Using NIRS-IVUS Imaging in Patients With Acute Myocardial Infarction

David Erlinge

COMBINE (OCT–FFR): A Prospective Natural History Study Using OCT Imaging in Patients With Diabetes

Elvin Kedhi

PROSPECT ABSORB: A Randomized Trial of Interventional Treatment of Vulnerable Plaques

Gregg W. Stone

Late-Breaking Science

NACMI: Outcomes from the North American COVID-19 STEMI Registry

Timothy Henry

COMPARE CRUSH: A Randomized Trial of Pre-hospital Crushed vs Uncrushed Prasugrel in STEMI

Georgios Vlachojannis

TICO-STEMI: A Randomized Trial of Ticagrelor Monotherapy vs Ticagrelor With Aspirin in STEMI

Byeong-Keuk Kim

Bivalirudin vs Heparin in Patients with Myocardial Infarction: An Individual Patient Data Pooled Analysis

Gregg W. Stone

Thursday, October 15, 2020

Late-Breaking Trials

SCOPE II: A Randomized Trial of Two Self-expanding TAVR Bioprostheses

Corrado Tamburino

REFLECT II: A Randomized Trial of a Cerebral Embolic Protection Device During TAVR

Jeffrey Moses

MITHRAS: A Randomized Trial of ASD Closure After TMVr

Philipp Lurz

Late-Breaking Science

Disrupt CAD III: Safety and Effectiveness of Intravascular Lithotripsy for Treatment of Severe Coronary Calcification

Dean Kereiakes

XIENCE 90/28: Assessment of Three-Month and One-Month DAPT After Everolimus-Eluting Stents in High-Bleeding Risk Patients

Roxana Mehran and Marco Valgimigli

DEFINE-PCI: One-Year Outcomes in Patients with Post-PCI Residual Ischemia

Manesh Patel

ULTIMATE: Three-Year Outcomes After IVUS-Guided vs Angiography Guided DES Implantation

Junjie Zhang

Friday, October 16, 2020

Late-Breaking Trials

FORECAST: A Randomized Trial of CTA/FFRCT Decision-making in Patients with Chest Pain

Nick Curzen

TARGET FFR: A Randomized Trial of Physiology-Guided PCI Optimization

Damien Collison

DEFINE-FLOW: An Observational Study of Deferred Lesions After FFR and CFR Assessment

Nils Johnson

Late-Breaking Science

SOLVE-TAVI: One-Year Outcomes of a Factorial Randomized Trial of Self-expandable vs Balloon-expandable TAVR and General vs Local Anesthesia

Hans-Josef Feistritzer

STS/ACC TVT Registry: Cerebral Embolic Protection and TAVR Outcomes

David J. Cohen

MitraBridge: Outcomes of MitraClip Treatment as Bridge Therapy to Heart Transplantation

Cosmo Godino

Global EXPAND: One-Year Outcomes with Third Generation MitraClip NTR and XTR Systems

Saibal Kar

Saturday, October 17, 2020

Late-Breaking Trials

Host-Reduce-Polytech-ACS: A Randomized Trial of Durable Polymer vs Bioabsorbable Polymer DES in Patients with Acute Coronary Syndromes

Hyo-Soo Kim

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Robert Byrne

OPTIMIZE: A Randomized Trial of a Novel, Ultra Low Profile Fixed-Wire DES

Dean Kereiakes

Late-Breaking Science

IREMMI: Outcomes of MitraClip in Patients With Acute Mitral Regurgitation in AMI With and Without Cardiogenic Shock

Rodrigo Estevez-Loureiro

SCOPE I: One-Year Results From a Randomized Trial of Self-expanding versus Balloon-expandable TAVR

Thomas Walther

TRANSIT: Treatment of Failed TAVR with TAVR

Luca Testa

PARTNER 2: Five-Year Follow-Up From the Aortic Valve-in-Valve Registries

John Webb

Sunday, October 18, 2020

Endovascular Late Breaking Clinical Trial and Science Session

VOYAGER PAD: Long-term Safety of Drug-Coated Devices in Peripheral Artery Revascularization

Connie Hess

IN.PACT BTK: A Randomzied Trial of Drug-Coated Balloon Angioplasty in the Infrapopliteal Arteries

Antonio Micari

ILLUMENATE: Four-Year Results with a Low-Dose Paclitaxel Drug-Coated Balloon in De Novo And Restenotic Femoropopliteal Lesions

Andrew Holden

TANGO: A Randomized Dose-Escalation Trial of Temsirolimus Adventitial Delivery to Improve Below the Knee Outcomes

Ehrin Armstrong

FLASH Registry: Acute Hemodynamic Improvement With Percutaneous Mechanical Thrombectomy in a Real-world Pulmonary Embolism Population

Catalin Toma

Anatomy of Human Accessory Renal Artery Peri-Arterial Renal Sympathetic Nerve for Renal Denervation

Yu Sato

Receive updates on Twitter at http://twitter.com/TCTConference and http://twitter.com/crfheart.

About CRF

The Cardiovascular Research Foundation (CRF) is one of the world’s leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For nearly 30 years, CRF has helped pioneer medical advances and educated doctors on the latest treatments for heart disease. CRF is comprised of the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Now in its 32nd year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit www.crf.org and www.tctconference.com.